Alphatec (ATEC) Stock Price, News & Analysis

Company Overview

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Key Stats

• Today's Range: $9.79 to $10.54
• 50-Day Range: $9.27 to $12.53
• 52-Week Range: $4.88 to $14.54
• Volume: 2.84 million shs
• Average Volume: 1.98 million shs
• Market Capitalization: $1.51 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.67
• Consensus Rating: Moderate Buy

Alphatec Stock Analysis - MarketRank™

Alphatec scored higher than 83% of companies evaluated by MarketBeat, and ranked 172nd out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alphatec has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Alphatec has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alphatec are expected to grow in the coming year, from ($1.08) to ($0.65) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alphatec is -8.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alphatec is -8.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alphatec has a P/B Ratio of 18.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.72% of the float of Alphatec has been sold short.

Short Interest Ratio / Days to Cover

Alphatec has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Alphatec has recently increased by 8.35%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alphatec does not currently pay a dividend.

Dividend Growth

Alphatec does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.3 / 5
• Environmental Score: -1.67

Percentage of Shares Shorted

9.72% of the float of Alphatec has been sold short.

Short Interest Ratio / Days to Cover

Alphatec has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Alphatec has recently increased by 8.35%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.53

News Sentiment

Alphatec has a news sentiment score of 1.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Alphatec this week, compared to 5 articles on an average week.

Search Interest

Only 3 people have searched for ATEC on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

1 people have added Alphatec to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alphatec insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,828,060.00 in company stock.

Percentage Held by Insiders

22.80% of the stock of Alphatec is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.35% of the stock of Alphatec is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ATEC Stock Analysis - Frequently Asked Questions

How have ATEC shares performed this year?

Alphatec's stock was trading at $9.18 at the beginning of the year. Since then, ATEC shares have increased by 13.8% and is now trading at $10.45.
View the best growth stocks for 2025 here.

How were Alphatec's earnings last quarter?

Alphatec Holdings, Inc. (NASDAQ:ATEC) posted its quarterly earnings data on Wednesday, February, 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.04. The medical technology company had revenue of $176.79 million for the quarter, compared to analysts' expectations of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative trailing twelve-month return on equity of 541.39%.

How do I buy shares of Alphatec?

Shares of ATEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alphatec own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alphatec investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD) and Meta Platforms (META).

Company Calendar

• Last Earnings: 2/26/2025
• Today: 4/02/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:ATEC
• CIK: 1350653
• Web: www.atecspine.com
• Phone: (760) 431-9286
• Fax: 800-922-1356
• Employees: 700
• Year Founded: 1990

Price Target and Rating

• Average Stock Price Target: $17.67
• High Stock Price Target: $21.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +72.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-186,640,000.00
• Net Margins: -31.06%
• Pretax Margin: -31.15%
• Return on Equity: -541.39%
• Return on Assets: -22.99%

Debt

• Debt-to-Equity Ratio: 30.21
• Current Ratio: 2.32
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: $611.56 million
• Price / Sales: 2.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.57 per share
• Price / Book: 18.02

Miscellaneous

• Outstanding Shares: 144,149,000
• Free Float: 109,481,000
• Market Cap: $1.48 billion
• Optionable: Optionable
• Beta: 1.39